Category:Atypical antipsychotic: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Category: Drugs]][[Category: | [[Category: Drugs]][[Category: Brexpiprazole ]] | ||
[[:Category: | [[:Category: Antipsychotic Drug | '''Antipsychotic Drug''']] | ||
'''Drug class: [[:Category: | '''Drug class: [[:Category: Brexpiprazole | Brexpiprazole]] | ||
'''Brexpiprazole (Rexulti)'''(中文:[[銳思定]]) | '''Brexpiprazole (Rexulti)'''(中文:[[銳思定]]) | ||
Revision as of 03:29, 8 July 2024
Drug class: Brexpiprazole
Brexpiprazole (Rexulti)(中文:銳思定)
Common Strengths of Brexpiprazole Tablet
Brexpiprazole tablets are available in the following strengths:
- 0.25 mg
- 0.5 mg
- 1 mg
- 2 mg
- 3 mg
- 4 mg
Drug Trade Names of BrexpiprazoleBrexpiprazole Tablet
Rexulti is the trade name for Brexpiprazole:
Drug Usage
Brexpiprazole is used for:
- Treatment of schizophrenia
- Adjunctive treatment of major depressive disorder (MDD)
- Treatment of agitation associated with dementia due to Alzheimer's disease
Mechanism of Action
Brexpiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. It modulates dopaminergic and
serotonergic activity to improve symptoms of schizophrenia and depression
Route of Administration
Brexpiprazole is administered orally in the form of tablets or liquid solution.
Dosages
- Schizophrenia (Adults): Initial dose of 1 mg once daily, titrated to 2 mg on Day 5 to 7, and up to 4 mg by Day 8. Target dose: 2 to 4 mg daily. Maximum dose: 4 mg/day.
- Depression (Adults): Initial dose of 0.5 mg or 1 mg once daily, titrated to 2 mg daily. Maximum dose: 3 mg/day.
- Pediatric Schizophrenia (13-17 years): Initial dose of 0.5 mg once daily, titrated to 1 mg on Day 5 to 7, and up to 2 mg by Day 8. Maximum dose: 4 mg/day.
For patients with moderate to severe renal impairment, the dosage of brexpiprazole should be reduced to a maximum of 3 mg per day for schizophrenia and 2 mg per day for MDD.
No adjustment is needed for mild renal impairment.
Side Effects
| Frequency | Adverse reactions |
|---|---|
| Common | Weight gain |
| Akathisia (feeling of restlessness, constant urge to move) | |
| Headache | |
| Drowsiness/sleepiness | |
| Dizziness | |
| Nausea | |
| Constipation | |
| Indigestion/heartburn | |
| Increased appetite | |
| Fatigue/tiredness | |
| Tremor | |
| Stuffy or runny nose | |
| Uncommon | Neuroleptic malignant syndrome (high fever, muscle stiffness, confusion) |
| Tardive dyskinesia (uncontrolled muscle movements) | |
| High blood sugar/diabetes | |
| Orthostatic hypotension (dizziness when standing up) | |
| Seizures | |
| Low white blood cell count | |
| Difficulty swallowing | |
| Suicidal thoughts or behaviors (especially in young adults) | |
| Compulsive behaviors (gambling, sexual urges, binge eating) | |
| Cognitive impairment | |
| Impaired body temperature regulation | |
| Stroke in elderly patients with dementia-related psychosis | |
| Allergic reactions (rash, itching, difficulty breathing) |
Pharmacokinetics
- Absorption
- Peak plasma concentration within 4 hours.
- Metabolism
- Primarily metabolized by CYP3A4 and CYP2D6.
- Excretion
- 25% in urine and 46% in feces. Terminal elimination half-life is approximately 91 hours.
Initial effects: Some patients may begin to see improvements within 1 to 2 weeks of starting treatment.
Full Therapeutic Effects: The best results are typically observed after 4 to 6 weeks for schizophrenia and major depressive disorder (MDD) For agitation associated with
dementia due to Alzheimer's disease, significant results may be seen in about 12 weeks.
Drug Precautions
Increased risk in elderly patients
- Should not be used to treat dementia-related psychosis in older adults due to increased risk of stroke and death
- May cause drowsiness, dizziness, and difficulty swallowing in elderly patients, increasing the risk of falls and choking
Suicidal thoughts in young people
- May increase the risk of suicidal thoughts in young people under 24 years old, especially in the first few months of treatment or with dose changes
- Close monitoring is required for children/teens taking aripiprazole
Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.
Dysphagia
- Esophageal dysmotility and aspiration associated with antipsychotic drug use
- Use cautiously in patients at risk for aspiration pneumonia
Monitoring Requirements
- Regular monitoring of blood sugar levels, weight, and signs of extrapyramidal symptoms
- Perform complete blood count (CBC) in patients with pre-existing low white blood cell count (WBC) or history of drug-induced leukopenia/neutropenia
- Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope
Drug Interactions
- Avoid strong CYP3A4 inducers and inhibitors
FAQ
How Should I Take the Tablet?
- Take brexpiprazole once daily with or without food, at the same time each day.
What should I avoid while taking brexpiprazole?
- Avoid alcohol, and activities requiring alertness until you know how the medication affects you. Avoid overheating and dehydration
What Happens if I Miss a Dose?
- Take the missed dose as soon as you remember unless it is almost time for your next dose. Do not double doses.
Pages in category "Atypical antipsychotic"
The following 8 pages are in this category, out of 8 total.
